Trial Profile
Phase II Randomized, Open-Label Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 06 Jul 2011 Results will be reported at the 14th World Conference on Lung Cancer.
- 14 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Nov 2010 Additional trial identifiers (13421, I4E-MC-S001), trial centres identified as reported by ClinicalTrials.gov.